Trademark: 97037525
Status Date
Monday, December 18, 2023
Filing Date
Tuesday, September 21, 2021
Published for Opposition
Tuesday, March 15, 2022
Abandoned Date
Monday, December 18, 2023
5 Pharmaceuticals for reducing side effects or improving efficacy for cancer and oncology patients; pharmaceuticals for the prevention, treatment or management of superoxide mediated conditions; biotechnological preparations for medical use for the treatment of oncological disorders and treatment-related side effects
42 Research and development in the pharmaceutical and biotechnology fields
The mark consists of an abstract sword bisecting the divided outline of a shield.
Dec 18, 2023
Abandonment Notice E-Mailed - No Use Statement Filed
Dec 18, 2023
Abandonment - No Use Statement Filed
May 9, 2023
Notice Of Approval Of Extension Request E-Mailed
May 5, 2023
Sou Extension 2 Granted
May 5, 2023
Sou Extension 2 Filed
May 5, 2023
Sou Teas Extension Received
Oct 20, 2022
Notice Of Approval Of Extension Request E-Mailed
Oct 18, 2022
Sou Extension 1 Granted
Oct 18, 2022
Sou Extension 1 Filed
Oct 18, 2022
Sou Teas Extension Received
May 10, 2022
Noa E-Mailed - Sou Required From Applicant
Mar 15, 2022
Official Gazette Publication Confirmation E-Mailed
Mar 15, 2022
Published For Opposition
Feb 23, 2022
Notification Of Notice Of Publication E-Mailed
Feb 8, 2022
Approved For Pub - Principal Register
Feb 8, 2022
Examiner's Amendment Entered
Feb 8, 2022
Notification Of Examiners Amendment E-Mailed
Feb 8, 2022
Examiners Amendment E-Mailed
Feb 8, 2022
Examiners Amendment -Written
Jan 27, 2022
Notification Of Non-Final Action E-Mailed
Jan 27, 2022
Non-Final Action E-Mailed
Jan 27, 2022
Non-Final Action Written
Jan 24, 2022
Assigned To Examiner
Oct 26, 2021
Notice Of Design Search Code E-Mailed
Oct 24, 2021
New Application Office Supplied Data Entered
Sep 24, 2021
New Application Entered
Trademark Alertz updated from USPTO on 2030-01-24
